All In Biotech

Drug Trial Radar · NCT00346775

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects With Seasonal Allergic Rhinitis During a Three-week Cross-over Study

Last checked: Nov 20, 2026Latest source record: Jan 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

97

Actual

Start

May 1, 2006

Primary completion

Jun 29, 2006

Study completion Jun 29, 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 30, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

  • Beclomethasone dipropionateDrug

    Beclomethasone dipropionate

  • FlunisolideDrug

    Flunisolide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlations of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Preference Module With Treatment Satisfaction Questionnaire for Medicines (TSQM) Change Scores and Change in Mean Daily Reflective Total Nasal Symptom (rTNSS) ScoresTime frame: Day 1 to Day 23
  2. Correlation of EARNS-Q Preference Module With EARNS-Q Experience Module Change ScoresTime frame: Day 1 to Day 23

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Napa, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Walnut Creek, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.